Drug safety in Australia is regulated via the Office of Medicines Safety Monitoring (OMSM) (synonymous with Adverse Drug Reaction Advisory Committee), a branch of the Therapeutic Goods Administration (TGA). In New Zealand, Medsafe is the regulatory agency responsible for overseeing drug safety/ ...
Drug supply chain is very costly and is a well-recognized bottleneck at the design and managing of clinical trials. The innovative risk-based statistical approach to modelling drug supply demand for a single study is proposed. The approach uses the developed technique for predicting the number of ...
Major pharmaceutical and emerging biopharmaceutical companieshave a plethora of choices in utilizing contract-manufacturingorganizations (CMOs) available in the global market place for their custom synthesis needs. However, establishing a collaborative relationship with a few manageable and reliable...
The research-based pharmaceutical industry has always accommodated change, and like other businesses, is increasingly becoming cost constrained due in part to the rising investment required to develop new medicines and the global economic environment.
As the world economy and financial markets contracted in 2009, so
did the market for biopharmaceutical contract manufacturer services.
A screening compound collection is recognized as a valuable asset by most pharmaceutical companies and Compound Management is now a key component of the Drug Discovery process.